{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:52:12Z","timestamp":1781844732284,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","aaojournal.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ophtha.2017.12.008","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T14:28:44Z","timestamp":1517495324000},"page":"691-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)"],"prefix":"10.1016","volume":"125","author":[{"given":"Jo\u00e3o","family":"Figueira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Massin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-0833","authenticated-orcid":false,"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3238-9682","authenticated-orcid":false,"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Midena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Varano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":false,"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-4070","authenticated-orcid":false,"given":"Haralabos","family":"Eleftheriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Amaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ayello Scheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-4598","authenticated-orcid":false,"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3296-179X","authenticated-orcid":false,"given":"Dalila","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrina","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concei\u00e7\u00e3o","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Cunha-Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2017.12.008_bib1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2017.12.008_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-9394(76)90292-0","article-title":"Preliminary report on effects of photocoagulation therapy","volume":"81","author":"The Diabetic Retinopathy Study Research Group","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.008_bib3","first-page":"583","article-title":"Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group","volume":"88","author":"Photocoagulation treatment of proliferative diabetic retinopathy","year":"1981","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.008_bib4","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","article-title":"Early photocoagulation for diabetic retinopathy","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.008_bib5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2017.12.008_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ophtha.2005.10.012","article-title":"Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals","volume":"113","author":"Adamis","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.008_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.eye.6702980","article-title":"Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up","volume":"23","author":"Arevalo","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2017.12.008_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","article-title":"Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy","volume":"118","author":"Adamis","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.008_bib9","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2017.12.008_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000442026","article-title":"Ranibizumab for high-risk proliferative diabetic retinopathy: an exploratory randomized controlled trial","author":"Figueira","year":"2015","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2017.12.008_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/ICB.0000000000000306","article-title":"Peculiarities of vitrectomy and morphologic changes in the epiretinal membrane after intravitreal aflibercept in patients with severe proliferative diabetic retinopathy","volume":"11","author":"Umanets","year":"2017","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.ophtha.2017.12.008_bib12","first-page":"1","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase\u00a02b,\u00a0n","volume":"6736","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2017.12.008_bib13","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/bjo.2008.155663","article-title":"Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy","volume":"93","author":"Gonz\u00e1lez","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.008_bib14","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.008_bib15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/IAE.0b013e31827b63f3","article-title":"Intravitreal Bevacizumab (Avastin) for persistent new vessels in Diabetic retinopathy (IBEPE Study): 1-Year Results","volume":"33","author":"Cintra","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.008_bib16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1600-0420.2007.01042.x","article-title":"Intravitreal bevacizumab (Avastin\u00ae) in proliferative diabetic retinopathy","volume":"86","author":"Minnella","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.008_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/112067210801800215","article-title":"Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: A randomized double-masked clinical trial","volume":"18","author":"Mirshahi","year":"2008","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.008_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.008_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1600-0420.2007.01056.x","article-title":"Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study)","volume":"86","author":"Tonello","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.008_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/jop.2012.0202","article-title":"Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy","volume":"29","author":"Yang","year":"2013","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2017.12.008_bib21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A\u00a0brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ophtha.2017.12.008_bib22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1463-1326.2011.01415.x","article-title":"New approaches to the treatment of diabetic retinopathy","volume":"13","author":"Porta","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2017.12.008_bib23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4155\/cli.11.13","article-title":"Developing an international network for clinical research in ophthalmology: the European Vision Institute Clinical Research Network (EVICR.net)","volume":"1","author":"Cunha-Vaz","year":"2011","journal-title":"Clin Investig"},{"key":"10.1016\/j.ophtha.2017.12.008_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000378736","article-title":"European Network of Clinical Research in Ophthalmology. Information update-January 2015","volume":"53","author":"EVICR.net","year":"2015","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.ophtha.2017.12.008_bib25","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/IAE.0000000000000403","article-title":"Topical nepafenec in eyes with noncentral diabetic macular edema","volume":"35","author":"Friedman","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.008_bib26","unstructured":"Hamilton A, Ulbig M, Polkinghorne P. Management of Diabetic Retinopathy. 1st ed. Group BP ed. London; 1996."},{"issue":"5 Suppl","key":"10.1016\/j.ophtha.2017.12.008_bib27","first-page":"741","article-title":"ETDRS report number 7","volume":"98","author":"Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.12.008_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy","volume":"89","author":"Filho","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.12.008_bib29","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/IAE.0000000000001181","article-title":"Intravitreal bevacizumab for proliferative diabetic retinopathy","volume":"37","author":"Arevalo","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.12.008_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","article-title":"Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy","volume":"92","author":"Arevalo","year":"2008","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017321887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017321887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T04:52:27Z","timestamp":1532407947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642017321887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0161642017321887"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.008","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}